Reuters logo
BRIEF-Bluebird Bio announces clinical, biological outcomes
March 1, 2017 / 10:11 PM / 9 months ago

BRIEF-Bluebird Bio announces clinical, biological outcomes

March 1 (Reuters) - Bluebird Bio Inc:

* Announces clinical and biological outcomes for first patient with sickle cell disease treated with gene therapy

* Bluebird Bio - adverse events (AES) were consistent with busulfan conditioning, no AES related to lentiglobin drug product have been observed to date

* Patient has resumed regular school attendance and reports full participation in normal physical activities Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below